‘Remarkably High’ Prevalence of CKD Found in Thailand
Thailand has a “remarkably high” prevalence of CKD among individuals aged 35 years and older, according to Thai and Australian researchers.
Diagnosis & Disease Information
HoLEP Efficacy for BPH Increases with Prostate Size
The efficacy of holmium laser enucleation of the prostate (HoLEP) in the treatment of symptomatic BPH increases with prostate size, according to researchers in India.
Lower BPH Risk Linked to Greater Vegetable Intake
A diet high in vegetable intake is associated with a lower risk of surgically treated BPH, according to Australian researchers.
AHRQ Makes Safety Toolkits Available
The federal Agency for Healthcare Research and Quality (AHRQ) has published an updated series of safety toolkits that apply evidence-based practices to many settings.
Survey: Error-Reporting Systems Need Work
Doctors want to learn from each others’ mistakes, but concerns about confidentiality and retribution make them leery about formal reporting systems, according to a recent survey. As a result, “much important information remains invisible to institutions and the health care system.”
Contracts Would Replace Malpractice Suits
The think tank that developed the Health Savings Accounts is proposing that contracts replace lawsuits to compensate injured patients. These contracts would disregard fault and mandate full disclosure, while accounting for patient compliance and varying degrees of risk.
A Urologist Is Tripped Up By Saying Too Much
When the emergency department nurses had difficulty passing a urethral catheter, Dr. S was the urologist on call. One such case led to a malpractice suit.
Not Approvable Letter Issued on OTC Lovastatin
Merck has received a not approvable letter from the FDA to its New Drug Application seeking approval for over-the-counter (OTC) Mevacor (lovastatin) 20 mg.
Single-Tablet Combo for Greater BP Reduction Cleared
Tekturna HCT has been approved as a single-tablet combination of two medicines for high BP: tekturna (aliskiren), the first new type of antihypertensive drug in more than a decade, and the diuretic hydrochlorothiazide.
Agency to Review Study Data on Cholesterol-Lowering Drug
The FDA issued an Early Communication regarding its ongoing review of Vytorin (ezetimibe and simvastatin) based on preliminary results from the recently completed ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) study on this cholesterol-lowering drug.
- Loading...
Loading...
Next post in FDA News
Loading... 
Loading...